Detalles de la búsqueda
1.
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Nephrol Dial Transplant
; 38(2): 372-383, 2023 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35451488
2.
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Nephrol Dial Transplant
; 37(7): 1261-1269, 2022 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34850173
3.
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Diabetes Obes Metab
; 23(2): 599-608, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217117
4.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Diabetes Obes Metab
; 23(2): 549-560, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33145944
5.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Diabetes Obes Metab
; 22(9): 1516-1526, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32311204
6.
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
Diabetes Obes Metab
; 22(11): 2151-2160, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32691513
7.
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
Br J Clin Pharmacol
; 85(8): 1820-1828, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31077437
8.
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
Diabetes Obes Metab
; 19(11): 1635-1639, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28417527
9.
Importance of sulfur-containing metabolites in discriminating fecal extracts between normal and type-2 diabetic mice.
J Proteome Res
; 13(10): 4220-31, 2014 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24991707
10.
Retinal proteome alterations in a mouse model of type 2 diabetes.
Diabetologia
; 57(1): 192-203, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24078137
11.
Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.
Int J Biol Macromol
; 265(Pt 1): 130962, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38503370
12.
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Diabetes Res Clin Pract
; 204: 110908, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37805000
13.
Innovations in phenotyping of mouse models in the German Mouse Clinic.
Mamm Genome
; 23(9-10): 611-22, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22926221
14.
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
Blood
; 116(9): 1498-505, 2010 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20519624
15.
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Kidney Int Rep
; 7(1): 36-45, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35005312
16.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Diabetes Care
; 45(12): 2991-2998, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972218
17.
Validation of Candidate Phospholipid Biomarkers of Chronic Kidney Disease in Hyperglycemic Individuals and Their Organ-Specific Exploration in Leptin Receptor-Deficient db/db Mouse.
Metabolites
; 11(2)2021 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33546276
18.
Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
Diabetes Ther
; 11(5): 1135-1146, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32274678
19.
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Lancet Diabetes Endocrinol
; 8(10): 845-854, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32946821
20.
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Sci Rep
; 10(1): 22396, 2020 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33372185